Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $12.87B | $119.02 | $122.60 | 3.01% | Buy | 5 | 37.76% | 129.12% | 172.24% | 136.79% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $32.46B | $242.61 | $360.56 | 48.62% | Strong Buy | 16 | 23.14% | 32.82% | 186.00% | 45.31% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $6.30B | $80.80 | $91.29 | 12.98% | Strong Buy | 7 | 19.26% | 32.32% | 38.00% | 27.74% | |||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $3.33B | $26.46 | $36.67 | 38.58% | Strong Buy | 6 | 19.96% | 108.00% | 162.86% | 73.53% | |||
| ADMA | ADMA BIOLOGICS INC | $2.25B | $10.05 | $17.50 | 74.13% | Buy | 3 | 15.93% | 22.26% | 83.21% | 49.64% | |||
| HALO | HALOZYME THERAPEUTICS INC | $12.21B | $107.62 | $101.83 | -5.38% | Buy | 6 | 10.33% | 46.58% | 769.40% | 42.85% | |||
| VCEL | VERICEL CORP | $2.23B | $43.57 | $62.67 | 43.83% | Strong Buy | 3 | 14.65% | 42.24% | 22.72% | 16.72% | |||
| KRYS | KRYSTAL BIOTECH INC | $10.16B | $343.34 | $361.43 | 5.27% | Strong Buy | 8 | 24.95% | 16.98% | 63.71% | 57.71% | |||
| RPRX | ROYALTY PHARMA PLC | $35.49B | $61.73 | $62.60 | 1.41% | Strong Buy | 5 | 14.95% | 48.38% | 42.19% | 20.83% | |||
| TGTX | TG THERAPEUTICS INC | $7.91B | $51.69 | $63.75 | 23.33% | Buy | 4 | 27.25% | 8.54% | 101.32% | 37.33% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $720.33M | $12.13 | $26.88 | 121.56% | Strong Buy | 8 | 19.24% | 15.40% | 77.72% | 55.88% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $13.42B | $69.33 | $91.00 | 31.26% | Strong Buy | 16 | 13.18% | 159.07% | 25.90% | 13.97% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $250.83M | $3.17 | $10.50 | 231.23% | Strong Buy | 2 | 14.12% | 21.45% | 35.21% | 27.26% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $5.80B | $290.71 | $342.88 | 17.94% | Strong Buy | 8 | 15.30% | 13.32% | 29.02% | 12.85% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $139.93B | $552.06 | $562.71 | 1.93% | Strong Buy | 17 | 9.10% | 12.65% | 36.48% | 26.94% | |||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $16.37B | $252.16 | $278.81 | 10.57% | Strong Buy | 16 | 5.17% | 24.24% | 43.06% | 18.66% | |||
| SPRO | SPERO THERAPEUTICS INC | $71.63M | $1.23 | N/A | N/A | N/A | N/A | -14.78% | 128.15% | N/A | N/A | |||
| TECH | BIO-TECHNE CORP | $11.35B | $72.48 | $68.33 | -5.72% | Hold | 11 | 8.33% | 54.53% | 19.73% | 16.13% | |||
| MDXG | MIMEDX GROUP INC | $648.63M | $4.45 | $7.00 | 57.30% | Strong Buy | 3 | -0.77% | 70.85% | 13.77% | 10.58% | |||
| EXEL | EXELIXIS INC | $13.48B | $54.39 | $52.00 | -4.39% | Hold | 11 | 10.64% | 11.32% | 66.89% | 49.45% | |||
| UTHR | UNITED THERAPEUTICS CORP | $22.70B | $529.14 | $648.40 | 22.54% | Strong Buy | 10 | 10.81% | 7.42% | 30.47% | 27.01% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $86.57B | $840.84 | $800.74 | -4.77% | Strong Buy | 19 | 8.27% | 15.23% | 24.05% | 18.28% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.33B | $39.93 | $42.33 | 6.02% | Hold | 6 | 11.43% | 16.96% | 23.24% | 16.92% | |||
| INCY | INCYTE CORP | $26.04B | $128.47 | $118.63 | -7.66% | Buy | 16 | 4.41% | 7.48% | 12.85% | 10.36% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.